Company intelligence / Profile preview
Hunan Nucien Pharmaceutical
Hunan Sheng, Chinanucien.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Peramivir inhalation solution is in Phase 3 trials for uncomplicated influenza; mefunidone hydrochloride is in Phase 2 for diabetic nephropathy, with positive Phase 1 safety and PK; multiple approved products on market for viral and cardiovascular indications. The company has over 25 clinical trials, focusing on innovative drug development in antiviral, cardiovascular, and metabolic disease areas[1][3].
- Therapeutic areas
- EndocrinologyNephrologyInfectious DiseasesDermatologyCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Hunan Nucien Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hunan Nucien Pharmaceutical.